LIXTE Biotechnology Regains Nasdaq Compliance with $5M Financing

LIXTE Biotechnology Holdings has regained compliance with Nasdaq's continued listing requirements after closing a $5.0 million placement and a $1.5 million registered direct offering. The company had previously fallen short of the minimum equity requirement of $2.5 million. The Nasdaq Hearings Panel has notified the company of its regained compliance.

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company, has regained compliance with Nasdaq's continued listing requirements. The company announced that it has received a letter from the Nasdaq Hearings Panel confirming its compliance with Nasdaq’s Listing Rule 5550(b)(1), the "Equity Rule," which requires a minimum equity requirement of $2.5 million for continued listing on the Nasdaq Capital Market [1].

The compliance was achieved following the company's closing of a $5.0 million placement and a $1.5 million registered direct offering, both announced on July 2, 2025, and July 8, 2025, respectively [1]. Geordan Pursglove, the company's Chief Executive Officer, stated, "Regaining compliance underscores the Company’s dedication to its Nasdaq listing and to fostering LIXTE’s financial health, as it continues to pursue its promising clinical trials in ovarian clear cell carcinoma, metastatic colon cancer, and advanced soft tissue sarcoma, among other opportunities" [1].

LIXTE Biotechnology Holdings is focused on developing new targets for cancer drug development and commercializing cancer therapies. The company's lead clinical candidate, LB-100, is a first-in-class PP2A inhibitor that has shown potential to enhance cancer treatment efficacy and improve patient outcomes. LB-100 is part of a pioneering effort in an entirely new field of cancer biology – activation lethality – which is advancing a new treatment paradigm [1].

The company's regained compliance is significant for investors as it ensures continued access to the public capital markets. However, the press release also highlights past compliance issues with Nasdaq, raising concerns about the company's financial stability and its ability to maintain future compliance. The company's dependency on external funding to meet minimum equity requirements is a notable factor [2].

References:
[1] https://ir.lixte.com/news-events/press-releases/detail/128/lixte-biotechnology-holdings-regains-compliance-with-nasdaqs-continued-listing-requirements
[2] https://www.quiverquant.com/news/LIXTE+Biotechnology+Holdings%2C+Inc.+Regains+Nasdaq+Compliance+Following+Successful+Capital+Raise